EPSTEIN ROBERT S 4

What Happened
Robert S. Epstein, a non-employee director of Fate Therapeutics (FATE), was granted equity awards on 2026-06-12 representing 87,900 shares (reported as a derivative acquisition). The Form 4 reports an acquisition price of $0.00, indicating these are option/award shares rather than a cash purchase of stock. This is a compensation award (routine director grant), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-12; Form 4 filed: 2026-06-15 (filing appears timely).
• Transaction type/code: Award/Grant (A) — derivative equity award (options).
• Shares/units granted: 87,900 (reported acquisition price $0.00).
• Shares owned after transaction: not specified in this filing.
• Footnotes: (F1) Grant made under the Issuer’s Amended and Restated Non-Employee Director Compensation Policy (annual director grant). (F2) Options vest and become exercisable on the earlier of June 12, 2027 or the 2027 Annual Meeting, subject to continued Board service.
• No 10b5-1 plan, tax-withholding, or cash exercise reported in this filing.

Context
These awards are standard annual equity compensation for non-employee directors and are derivative (options) that do not convert to exercisable shares until they vest (approximately one year, per footnote). Because this is a routine director grant rather than a market purchase or sale, it should be viewed as compensation, not a direct signal of the insider buying or selling shares.